Backs FY25 adjusted EBITDA view $150M-$200M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Reports 656% Net Income Surge
- Emergent BioSolutions Stockholders Elect Directors at Meeting
- Emergent BioSolutions announces $65M agreement to provide Ontario with NARCAN
- EBS Upcoming Earnings Report: What to Expect?
- Emergent Biosolutions: Strategic Share Repurchase and Diversified Revenue Streams Signal Strong Buy Opportunity